Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the FlowPath Lung Test, a non-invasive diagnostic tool using flow cytometry on sputum samples, to detect early-stage lung cancer in high-risk individuals. Participants have existing lung nodules between 6 and less than 30 millimeters in diameter, identified by low-dose computed tomography LDCT. The study focuses on assessing how sensitive and specific this test is for identifying lung cancer among those at elevated risk. Participants provide sputum samples for diagnostic testing with the FlowPath Lung Test within 12 weeks of their baseline CT scan. The study involves standard medical treatment and follow-up as per the institutions usual care. The lung nodules considered are either new, increasing, or stable for up to six months, and in cases of multiple nodules, the most suspicious nodule is selected for analysis. During the study, researchers will monitor participants for up to 24 months following the baseline sputum sample to measure the tests ability to detect early-stage lung cancer. Participants medical information related to their standard care follow-up will be collected. The primary outcome is the detection of early-stage lung cancer using the FlowPath Lung Test over this follow-up period, with ongoing standard medical care continuing throughout the study.
Actively Recruiting
Researchers are investigating how the design of removable cast walkers RCWs affects their usability and adherence among people with diabetic foot ulcers DFUs. Over 30% of people with diabetes will develop DFUs, which often do not heal and can lead to amputation. This pilot study aims to provide data to support a larger trial evaluating how different RCW designs impact adherence and healing outcomes, focusing on biomechanical and self-reported usability measures. Participants will be randomly assigned to use one of two types of RCWs a tall, knee-high removable cast walker with an offloading insole, or a short, ankle-high removable cast walker paired with an external shoe lift and diabetic shoe on the opposite foot. The study will assess adherence during weight-bearing activities and compare biomechanical and usability factors between these designs over a 28-day period. During the study, participants will be monitored for their adherence to wearing the assigned RCW, healing progress of their foot ulcers at clinical visits, and the cumulative tissue stress on the foot. Researchers will collect data on offloading adherence daily and evaluate healing at multiple clinical visits throughout the 28 days. This study is sponsored by Rosalind Franklin University of Medicine and Science and seeks to better understand how device design influences treatment adherence and outcomes in diabetic foot ulcer care.
Actively Recruiting
Healthy Volunteer
This research aims to study how switching from menthol to non-menthol cigarettes affects markers of inflammation in the body, which can indicate risk for heart disease. The study focuses on adult smokers who currently use menthol cigarettes and investigates changes in their smoking behavior, feelings related to smoking, and biomarkers of inflammation as a subclinical measure of cardiovascular health. Participants who smoke menthol cigarettes will take part in a five-week study. The first week is a baseline period where they continue smoking menthol cigarettes. Then, for the following four weeks, they will switch to study-provided non-menthol cigarettes that closely match their usual brand. Researchers will collect blood samples at four points to analyze inflammation markers and tobacco exposure. Participants will also report their smoking patterns and subjective experiences using ecological momentary assessment methods. During the study, participants will visit regularly for blood sample collection and assessments of smoking behavior, cravings, and feelings related to smoking. The primary outcomes include measuring high sensitivity C-reactive protein, fibrinogen, and a cytokine panel after four weeks of switching cigarettes. Secondary measures include blood pressure and heart rate. The total participation time is five weeks, including baseline and switching periods, with ongoing monitoring of biomarkers and subjective responses.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years. Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan. Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of atorvastatin 40 mg daily compared to a matching placebo in adults aged 75 years and older who live in the community and do not have cardiovascular disease or dementia. This large, randomized, placebo-controlled study aims to understand whether statins can reduce death, dementia, persistent disability, mild cognitive impairment, and cardiovascular events in this older population. The study is conducted at about 100 sites across the U.S. and includes both VA and non-VA centers. Participants will be randomly assigned to take either atorvastatin 40 mg or a placebo pill daily for up to 5 years, with an expected median follow-up of about 3.8 years. Study medication will be mailed directly to participants every 90 days. Some participants will have blood samples taken at baseline and again at 3 months to measure lipid levels, and additional physical and cognitive function tests will be performed. Enrollment can occur in person or remotely through telehealth, and community groups are involved in recruitment efforts. During the study, participants will be contacted annually by a central call center to assess cognitive and physical function using phone-based questionnaires. If certain signs are detected, in-person assessments and interviews with informants will be conducted. Researchers will also gather information on cardiovascular events from medical records and national databases. The study will monitor outcomes related to dementia diagnosis and disability over four years, with the total participation lasting up to five years.
Actively Recruiting
Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.
Actively Recruiting
Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.
Actively Recruiting
Researchers are studying atopic dermatitis AD in adolescents and adults to better understand the unmet needs across this condition and to observe how systemic treatments work in real-world settings. This observational study aims to explore patients journeys, including factors like age, skin color, flare triggers, past treatment responses, comorbidities, and lesion characteristics. It involves multiple countries and diverse populations to capture a broad picture of treatment impacts over time. The study follows patients who begin or switch any systemic treatment for AD, such as biologics, oral Janus kinase inhibitors, cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil, as prescribed by their doctors based on local guidelines. Researchers do not assign treatments but collect information on treatment choices and changes during standard care. This registry will track treatment sequences, interruptions, dose changes, and reasons for starting or stopping treatments over a five-year period. Participants will be followed for up to five years to monitor their treatment experience and disease progression. Data collection includes assessments of disease severity using tools like the Eczema Area and Severity Index EASI, body surface area affected, and global assessments of AD. Patient-reported outcomes such as itch, skin pain, sleep disturbance, quality of life, work productivity, and treatment satisfaction will also be recorded. Safety will be monitored through reports of adverse events. The study collects demographics, comorbid conditions, healthcare visits, and medication use to provide a comprehensive view of AD management in everyday care.